Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day. In a population of patients with chronic bronchitis, acute bacterial exacerbations of bronchitis are frequently seen (4). Such exacerbations often cause worsening of other comorbid conditions and contribute to hospitalization and indirectly to death. Although there has been debate about the need for and the efficacy of antimicrobial therapy in this setting (2, 10, 18), most physicians continue to treat welldocumented bacterial exacerbations of chronic bronchitis.
In a population of patients with chronic bronchitis, acute bacterial exacerbations of bronchitis are frequently seen (4) . Such exacerbations often cause worsening of other comorbid conditions and contribute to hospitalization and indirectly to death. Although there has been debate about the need for and the efficacy of antimicrobial therapy in this setting (2, 10, 18) , most physicians continue to treat welldocumented bacterial exacerbations of chronic bronchitis.
In the present study we compared the effects of a newer oral cephalosporin, cefixime, against those of cephalexin in the treatment of acute bacterial bronchitis. Cefixime is a ,-lactamase-stable cephalosporin that, because of its in vitro activity against gram-negative enteric pathogens, is considered the first broad-spectrum oral cephalosporin (19) . It has a sufficiently long half-life (4 h) to allow for once-daily dosing, and the peak level in serum after a 400-mg dose is 3 to 5 jxg/ml (7) . Cefixime has excellent in vitro activity against pathogens considered important in patients with bronchitis, including P-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae (MIC for 90%o of strains [MIC9], 0.25 ,ug/ml for both organisms) and Streptococcus pneumoniae (MIC90, 0.2 ,ug/ml) (3).
Cephalexin, the comparative agent, is often selected by clinicians in the empiric treatment of patients with acute bronchitis. It is active against S. pneumoniae (MICg, 3.1 ,ug/ml), B. catarrhalis (MIC90, 0.5 ,ug/ml), and P-lactamasenegative H. influenzae (MIC90, 6 .0 ,ug/ml) (9) and is generally well tolerated. A mean peak level of 10 ,ug/ml in serum is typical after a single 250-mg dose of cephalexin (12) . The ,-lactamase enzymes of B. catarrhalis are unique in that they do not hydrolyze cepahlexin as rapidly as ampicillin or cefaclor does (20 sputum sample, if available, was cultured. Patient compliance and final drug accountability were assessed by tablet counts and interviews. Patients were questioned about possible adverse reactions on each visit. Patients who had to discontinue either medication were monitored for 1 week or until the resolution of their symptoms.
The clinical response was defined as (i) cure, in which symptoms abated completely and there was no evidence of fever or sputum production at follow-up; (ii) improvement, in which symptoms were substantially alleviated but with incomplete resolution of evidence of infection; or (iii) failure or relapse, in which there was no response to therapy or there was clinical improvement followed by deterioration during or after treatment.
Exclusions after start of treatment. Of the 130 patients enrolled in the study, 44 were excluded after treatment had begun. The major reason for exclusion was due to failure to recover a pathogen on culture (23 patients). Others were excluded on the basis of lack of susceptibility data (nine patients), loss to follow-up (five patients), inadvertant removal from the study (four patients), and recovery of a resistant pathogen (three patients).
Data analysis. Patients were judged to be evaluable for data analysis if they had received the study drug for at least 7 days, unless they had a clear-cut failure of clinical response prior to that time. For evaluable patients, the mean base-line values of continuous variables of the two medication groups were compared by using the two-tailed t test for independent samples, and the contingency table x2 test was used to compare group proportions (see Table 1 ). Clinical outcomes among patient subgroups defined by pathogen or treatment were compared by using X2 contingency table analysis. Differences in medical and epidemiological characteristics of pathogen-defined groups were compared by the x2 contingency table test or the Fisher exact probability calculation procedure for categorical variables and analysis of variance for continuous variables. Side effects in all patients enrolled in the study were evaluated. Probability levels of 0.05 or smaller were used to indicate statistical significance. Table 1 , with the exception of atherosclerotic heart disease, which was found more frequently in the cephalexin group (63 versus 37%; P = 0.02).
Etiologic agents. The two leading causes of acute bacterial exacerbation of chronic bronchitis were H. influenzae and B. catarrhalis, accounting for over 60% of cases (Fig. 1) . The third largest category was a mixed group in which more than one pathogen was recovered (Fig. 2) influenzae isolates produced P-lactamase.
Response to therapy. There were 70.8% cures in the group treated with cefixime compared with 50% cures in the group treated with cephalexin (P < 0.05) ( Table 2 ). However, when the categories of cured and improved were combined, no significant difference was noted between treatment groups (95.8% for cefixime versus 84.2% for cephalexin; P = 0.06).
Side effects of therapy. For analysis of side effects, all 130 evaluable and nonevaluable patients who received either drug for any period of time were included. Twelve patients who received cefixime and three patients who received cephalexin reported side effects (Table 3) . These episodes were usually mild and were not always clearly related to the study drug, as many patients were receiving other medications. Six patients in the group treated with cefixime and no patients in the group treated with cephalexin experienced diarrhea (P = 0.013, Fisher exact test). While the diarrhea was mild in all instances, one patient requested to be removed from the study for this symptom. Mixed (see Fig. 2 When choosing an antimicrobial agent for empiric use, the prescribing physician should consider several factors, including the expected microbiology at the site of infection; the antibacterial spectrum associated with the possible agents of choice; and potential side effects, ease of administration, and cost of the possible agents. With regard to the microbiology associated with acute exacerbation of chronic bronchitis, it is noteworthy that in our population, B. catarrhalis was recovered as the predominant pathogen nearly as often as H. influenzae was (31.4 versus 33.7%, respectively). Furthermore, it was the most common organism recovered from patients with multiple (mixed) pathogens isolated from sputum culture. This is a particularly important finding since 37% of our B. catarrhalis isolates produced Gram-negative rods 3 b One patient in the group treated with cephalexin and three patients in the group treated with cefixime had ,-lactamase-producing H. influenzae; all patients were either cured or improved. P-lactamase and drugs such as ampicillin or amoxicillin, which are often selected in the empiric treatment of respiratory tract infections, would be ineffective against such organisms. The 37% incidence of P-lactamase production by our B. catarrhalis isolates was lower than expected: a previous study by Alvarez et al. (1) The significance of B. catarrhalis as a respiratory pathogen, particularly in patients with underlying pulmonary disease (8, 14) , and its susceptibility to antimicrobial agents (15, 17) have been reported previously. However, our data are in contrast to the findings of other investigators, who either failed to recover B. catarrhalis (5, 6, 13) or noted it to be a less frequent pathogen (10, 11, 16) in patients with chronic lung disease. Thus, the selection of an antimicrobial agent for treatment of an acute exacerbation of chronic bronchitis might preferably include a drug that is resistant to the effects of P-lactamase and that includes the currently recognized significant pathogens (H. influenzae, B. catarrhalis, and S. pneumoniae) in its spectrum.
In the present study, we compared the effects of cefixime and cephalexin in the treatment of patients with acute exacerbation of chronic bronchitis. Cefixime is a new orally administered cephalosporin which, because of its extremely broad spectrum of activity against a variety of aerobic gram-negative bacilli, as well as its 1-lactamase stability, is 
